Bailard Inc. lifted its holdings in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 19.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 75,300 shares of the biopharmaceutical company’s stock after acquiring an additional 12,000 shares during the quarter. Bailard Inc.’s holdings in Esperion Therapeutics were worth $4,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the stock. First Mercantile Trust Co. boosted its position in Esperion Therapeutics by 56.0% in the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 1,519 shares during the last quarter. Creative Planning purchased a new position in Esperion Therapeutics in the fourth quarter worth about $314,000. Oakmont Partners LLC purchased a new position in Esperion Therapeutics in the fourth quarter worth about $323,000. Teacher Retirement System of Texas purchased a new position in Esperion Therapeutics in the fourth quarter worth about $458,000. Finally, Voya Investment Management LLC boosted its position in Esperion Therapeutics by 12.7% in the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 806 shares during the last quarter. 92.25% of the stock is currently owned by institutional investors.

Esperion Therapeutics Inc (ESPR) opened at $69.99 on Wednesday. Esperion Therapeutics Inc has a 12 month low of $19.94 and a 12 month high of $82.18. The company has a market capitalization of $1,800.00, a PE ratio of -10.20 and a beta of 2.64.

In other news, Director Nicole Vitullo sold 11,674 shares of the firm’s stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $71.79, for a total value of $838,076.46. Following the transaction, the director now owns 3,177 shares of the company’s stock, valued at $228,076.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 32.50% of the stock is owned by company insiders.

Several research analysts have issued reports on the company. Citigroup cut Esperion Therapeutics from a “buy” rating to a “neutral” rating and raised their target price for the stock from $77.00 to $96.00 in a research report on Monday, January 22nd. Stifel Nicolaus set a $105.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 15th. BidaskClub raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 13th. Credit Suisse Group assumed coverage on Esperion Therapeutics in a research report on Wednesday, January 17th. They issued an “outperform” rating and a $103.00 target price on the stock. Finally, UBS Group set a $88.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Six equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $77.23.

COPYRIGHT VIOLATION WARNING: This report was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://theolympiareport.com/2018/02/14/esperion-therapeutics-inc-espr-position-raised-by-bailard-inc.html.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.